Cite
HARVARD Citation
Brown, S. et al. (n.d.). Clinical Utility of Measuring Infliximab (IFX) and Adalimumab (ADA) and Anti‐drug Antibody Levels Using the LabCorp Assay in Patients With Inflammatory Bowel Disease (IBD). American journal of gastroenterology. p. . [Online].